AI roundup: Your doctor’s choice for clinical AI | Amazon, Walmart & ecosystem AI | 2026’s top healthcare technology hazard

Meet the (lightly disputed) champion of healthcare AI suppliers.

It’s OpenEvidence, which has achieved a valuation of $12 billion after closing a funding round good for $250 million this week and topping $100 million in annualized revenue in 2025. As recently as October the company was “only” valued at $6 billion. It’s possible and maybe even likely that the healthcare divisions of AI bigwigs like Nvidia, OpenAI and Anthropic, not to mention Amazon, Microsoft and Google—or the AI portfolios of healthcare giants like Epic—are worth more than $12B. If so, the distinction would call for an asterisk, not a relinquishment of the title belt. In HealthExec’s opinion, anyway. Here’s why. 

• No other dedicated AI platform is more widely used than ‘OE’ by American physicians. It surely helps that the software is free to doctors, thanks to advertiser support. And it doesn’t hurt that the company maintains training-data partnerships with the likes of the American Medical Association and the New England Journal of Medicine. Those relationships clearly buttress the trustworthiness of OE’s algorithmic outputs for physician end-users. 
   
• In December alone, the company’s flagship product supported about 18 million clinical consultations from verified physicians in the U.S. That’s up from about 3 million consultations per month a year ago, OpenEvidence states in its Jan. 21 funding announcement. In 2025 more than 100 million patients were treated by an OE-equipped doctor. 
   
• OpenEvidence is effectively the default operating system of medical knowledge in the United States today. So posits Kareem Zaki, a keen observer of all things AI and entrepreneurial—and a partner at one of the investment firms leading OE’s latest funding round, Thrive Capital. “We are thrilled to partner with them,” Zaki adds in a line that could have gone without saying. 
   
• Is founder and CEO Daniel Nadler looking over his shoulder at OpenAI’s new ChatGPT Health or Anthropic’s fresh Claude Healthcare? Not really, he tells CNBC before stating OE is now used by 40% of U.S. doctors. “We’ve already gathered hundreds of millions of real-world clinical consultations from verified physicians,” he explains. “That feedback loop is incredibly hard to replicate. Even if someone copied the playbook today, they’d still be far behind because it’s not just the partnerships—it’s [also] the real-world usage data” that help set OpenEvidence apart. 
   
  • OpenEvidence announcement here, deep-dive coverage all over the place. 
     

Amazon is unveiling an agentic AI health assistant and broadening the reach of Alexa+. 

The timing suggests the Big Tech player’s intensifying desire to dive deeper into AI and ambient computing on all its consumer fronts. Pymnts highlights the development, noting similar stratagems from Walmart. “As Walmart and its peers expand into services, healthcare and financial products, leadership structures are being redesigned to support faster decision-making and tighter integration,” Pymnts reports. “The moves reflect organizational response to a world in which retail leaders must manage not just stores and supply chains, but ecosystems of technology, payments and partnerships.” More from the Jan. 22 article:

• Amazon’s decision to add an agentic AI assistant to its One Medical app marks a notable expansion of retail logic into healthcare. Pymnts points out that healthcare is “one of the most intimate and complex consumer domains.” The One Medical AI assistant is designed to answer health questions, manage medications and schedule appointments, “effectively collapsing the distance between information, action and care,” the outlet remarks. “While framed as a healthcare enhancement, the move reflects a familiar Amazon strategy: reduce friction, increase engagement and position the platform as an indispensable intermediary.”
   
• Taken together, the developments at Amazon and Walmart point to a retail landscape that is less about locations and more about touchpoints, Pymnts observes. “The store, the app, the cart, the payment method and even the healthcare assistant are all nodes in a distributed system designed to anticipate and respond to consumer needs in real time,” according to the outlet. “In this context, ‘meeting consumers where they are’ is not a metaphor. It is an operational mandate that touches every layer of the business, from AI development and financial partnerships to executive succession planning.”
   
  • Read the rest.
     

The No. 1 health technology hazard for 2026 is none other than misuse of AI chatbots.

ECRI, formerly the Emergency Care Research Institute, made the call after reviewing incident investigations, analyzing reporting databases and considering independent medical device tests. AI-related concerns have been rising in the annual exercise. Last year “Insufficient governance of AI in healthcare” was the No. 2 concern. In 2024, “Unintended consequences of technology adoption” came in at No. 4. 

• Two hazards that could be considered AI-adjacent also merit close watches in 2026, according to ECRI. These are “Unpreparedness for a ‘digital darkness’ event or a sudden loss of access to electronic systems and patient information” (No. 2) and “Health technology implementations that prompt unsafe clinical workflows (No. 9).
   
• Medicine remains a fundamentally human endeavor, ECRI president and CEO Marcus Schabacker, MD, PhD, comments in presenting the list. “While chatbots are powerful tools, the algorithms cannot replace the expertise, education and experience of medical professionals,” he adds. “Realizing AI’s promise while protecting people requires disciplined oversight, detailed guidelines and a clear-eyed understanding of AI’s limitations.”
   
  • Read the rest of the announcement here and/or download the full report here.
     

Also worthwhile:

• The AI startup soap opera riveting Silicon Valley …  Defections, secret conversations, deal talks that fizzled and a battle for control: The turmoil at Thinking Machines Lab is the artificial intelligence industry’s latest drama. (The New York Times) 
   
• Ethics is the defining issue for the future of AI. And time is running short. ... ‘Many companies still treat ethics as optional, while structural risks like bias, opacity and concentration of power remain entrenched.’ (Darden School of Business at the University of Virginia)
   

From HealthExec’s sibling news outlets:

• Healthcare executives push for federal AI policy framework that preempts state laws (Radiology Business)
   
• AI agent calling cath lab patients to help them prepare for treatment (Cardiovascular Business)